QT Imaging Announces Shipping Forty Breast Acoustic CT™ Scanners in 2025 and Meeting Its Revenue Guidance

Represents Year-Over-Year Revenue Growth of More than 285%

Sales Increase Driven by Shipment of Forty Scanners in 2025, up from Twelve in 2024

Expects to End Year in a Strong Financial Position to Support Continued Growth

NOVATO, Calif.--(BUSINESS WIRE)-- QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today confirms that it finalized the shipment of 40 scanners and met its revenue guidance of more than $18 million in 2025.

“2025 was a transitional year for QT Imaging as we moved from early commercialization to scaled execution. We met our objectives and shipped scanners in line with our plan, demonstrating growing market adoption and operational discipline. We expect to exit 2025 in a significantly stronger financial position, with projected year end cash of at least $10 million, compared to $1.2 million at the end of 2024,” said Dr. Raluca Dinu, Chief Executive Officer. “I would like to thank our board of directors, our team, all our commercial partners, and investors for their continued support as we position the Company for sustained growth.”

2025-2026 Sales Outlook

The Company reiterates $39 million in revenue in 2026 (shipment of 80 scanners). This target is in accordance with the minimum order quantities to be shipped per its Amended Distribution Agreement with its strategic business and distribution partner, NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, as well as its previously announced distribution agreement with Gulf Medical Co. in Saudi Arabia.

On December 23, 2025, the Company also furnished a Current Report on Form 8-K to the U.S. Securities and Exchange Commission, which includes copies of its unaudited pro forma condensed consolidated statement of operations and comprehensive loss as of and for the three months ended each of September 30, June 30, and March 31, 2025, and December 31, 2024. These financial statements are provided to present all information necessary to understand the Company’s enhanced profitability and meaningful debt reduction in 2025.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding QT Imaging Breast Acoustic CT imaging technology, and product sales growth and projected revenues and cash position. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, governmental approvals, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends, and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel, and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings’ filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

About QT Imaging

QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com.

Breast Acoustic CT^TM is a trademark of an affiliate of QT Imaging Holdings, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251224991067/en/

For investor and media inquiries, please contact:

Stephen Kilmer

Head of Investor Relations

Stephen.Kilmer@qtimaging.com

Direct: (646) 274-3580

Jay Jennings

Chief Financial Officer

Jay.Jennings@qtimaging.com

Source: QT Imaging Holdings, Inc.